Randomized controlled trial of deutetrabenazine for tardive dyskinesia: The ARM-TD study

Conclusions:
In patients with TD, deutetrabenazine was well tolerated and significantly reduced abnormal movements.

Classification of evidence:
This study provides Class I evidence that in patients with TD, deutetrabenazine reduces AIMS scores.

Source: Neurology - May 22, 2017 Category: Neurology Authors: Fernandez, H. H., Factor, S. A., Hauser, R. A., Jimenez-Shahed, J., Ondo, W. G., Jarskog, L. F., Meltzer, H. Y., Woods, S. W., Bega, D., LeDoux, M. S., Shprecher, D. R., Davis, C., Davis, M. D., Stamler, D., Anderson, K. E. Tags: Clinical trials Randomized controlled (CONSORT agreement), Class I ARTICLE Source Type: research